Mediators of chronic inflammation in polycystic ovarian syndrome

作者：Deligeoroglou E; Vrachnis N^*; Athanasopoulos N; Iliodromiti Z; Sifakis S; Iliodromiti S; Sinstatidis C; Creatsas G

来源：Gynecological Endocrinology, 2012, 28(12): 974-978.

DOI：10.3109/09513590.2012.683082

• Adhesion molecules
• ADMA
• AGEs
• CRP
• homocysteine
• IL-18
• IL-1a
• IL-1b
• IL-6
• osteoprotegerin
• PAI-1
• PCOS
• polycystic ovarian syndrome

Polycystic ovarian syndrome (PCOS) is an endocrine disorder affecting 5-10% of reproductive-age women. Hyperandrogenemia, which characterizes the syndrome, stimulates the maturation of adipocytes and favors central obesity. The linking hub between obesity and other metabolic manifestations of the syndrome seems to be chronic low-grade inflammation. We discuss the most reliable current data regarding the role of inflammatory mediators in PCOS, with particular focus on the genetic mechanisms implicated. C-reactive protein levels are 96% higher in PCOS patients than in healthy controls. Patients with the -308A polymorphism of the tumor necrosis factor-a gene have elevated androgens in comparison with carriers of the -308G. Interleukin 18(IL-18) is elevated in lean patients, with a further rise in the presence of obesity and insulin resistance. Polymorphisms of the IL-1a, IL-1b and IL-6 genes have also been associated with PCOS. Plasminogen activator inhibitor-1 levels are positively associated with the syndrome, and carriers of the 4G allele of the 4G/5G polymorphism are at risk of developing PCOS. Other mediators discussed include adhesion molecules, osteoprotegerin, asymmetric dimethylarginine, homocysteine and advanced glycation end-products. The elucidation of the pathogenetic mechanisms implicated in PCOS and their connection with low-grade inflammation may in the future offer the opportunity for the formulation of novel therapeutic strategies and individualized therapy for these patients.

• 出版日期2012-12